HRP20231142T3 - Kontrolirano oslobađanje 25-hidroksivitamina d - Google Patents
Kontrolirano oslobađanje 25-hidroksivitamina dInfo
- Publication number
- HRP20231142T3 HRP20231142T3 HRP20231142TT HRP20231142T HRP20231142T3 HR P20231142 T3 HRP20231142 T3 HR P20231142T3 HR P20231142T T HRP20231142T T HR P20231142TT HR P20231142 T HRP20231142 T HR P20231142T HR P20231142 T3 HRP20231142 T3 HR P20231142T3
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxyvitamin
- treatment process
- process according
- pharmaceutical preparation
- patient
- Prior art date
Links
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 title claims 4
- 235000021318 Calcifediol Nutrition 0.000 title claims 4
- 238000013270 controlled release Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 20
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims 16
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims 16
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 210000002966 serum Anatomy 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- -1 vitamin D compound Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Claims (18)
1. Farmaceutski pripravak koji sadrži oralnu formulaciju 25-hidroksivitamina D3 za uporabu u postupku liječenja sekundarnog hiperparatireoidizma kod ljudskog pacijenata koji ima kroničnu bolest bubrega,
naznačen time što postupak liječenja sadrži davanje pripravka pacijentu, pri čemu se pacijent liječi bez izazivanja suprafizioloških valova u razinama 25-hidroksivitamina D3u krvi,
i pri čemu farmaceutski pripravak sadrži 25-hidroksivitamin D3 zajedno sa sredstvom za modificiranje otpuštanja koje kontrolira brzinu otpuštanja spoja vitamina D iz oblika doziranja da se smanji Cmax i/ili odgodi Tmax i/ili smanji Cmax24hr/C24hr.
2. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 1 naznačen time što pacijent ima stadij 3 ili stadij 4 kronične bolesti bubrega.
3. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 1 ili 2 naznačen time što pacijent ima kroničnu bolest bubrega povezanu s brzinom glomerularne filtracije ispod 60 ml/min/1.73 m2.
4. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva naznačen time što pacijent kojeg treba liječiti ima niske ukupne razine 25-hidroksivitamina D u serumu na početku liječenja.
5. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 4, naznačen time što pacijent kojeg treba liječiti ima ukupnu razinu 25-hidroksivitamina D u serumu manju od 30 ng/mL na početku liječenja.
6. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 4 ili 5, naznačen time što postupak liječenja sadrži davanje pripravka pacijentu tako da se insuficijencija i/ili nedostatak 25-hidroksivitamina D kod pacijenta liječi bez izazivanja suprafizioloških valova u razinama 25-hidroksivitamina D3 u krvi.
7. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva naznačen time što je pacijent odrasli čovjek.
8. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva naznačen time što je sredstvo za modificiranje otpuštanja crijevna ovojnica.
9. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva naznačen time što u postupku liječenja:
(a) maksimalna koncentracija 25-hidroksivitamina D3 u serumu u intervalu doziranja (Cmax) je smanjena u usporedbi s Cmax za ekvivalentnu količinu 25-hidroksivitamina D3 primijenjenu bolus IV injekcijom i/ili oralnim oblikom doziranja, s trenutnim oslobađanjem, ili
(b) omjer maksimalne koncentracije u serumu unutar 24 sata nakon primjene 25-hidroksivitamina D3 i koncentracije 24 sata nakon primjene (Cmax24h/C24h) smanjen je u usporedbi s Cmax24h /C24h, za ekvivalentnu količinu od 25-hidroksivitamina D3 primijenjenog bolus IV injekcijom i/ili oralnim oblikom doziranja, s trenutnim oslobađanjem, ili
(c) vrijeme u kojem koncentracija 25-hidroksivitamina D3 u plazmi dosegne svoj maksimum u intervalu doziranja nakon primjene (Tmax) je povećano u usporedbi s Tmaxom za ekvivalentnu količinu 25-hidroksivitamina D3 primijenjenog bolus IV injekcijom i/ili oralnim oblikom doziranja, s trenutačnim oslobađanjem.
10. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 9, naznačen time što je Cmax smanjen za faktor od najmanje 20%.
11. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 9, naznačen time što je Tmax povećan za faktor od najmanje 25%.
12. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 9, naznačen time što je Cmax24hr/C24h smanjen za faktor od najmanje 20%.
13. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva, naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje u količinama doziranja od 1 do 100 µg, poželjno od 5 do 100 µg dnevno.
14. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva, naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje u količinama doziranja od 200 do 400 µg.
15. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od prethodnih zahtjeva, naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje u količinama doziranja od 5 do 80 µg, poželjno od 30 do 80 µg, poželjnije od 30 µg do 60 µg.
16. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 15, naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje u količini doziranja od 10 µg.
17. Farmaceutski pripravak za uporabu u postupku liječenja prema zahtjevu 15 naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje u količini doziranja od 30 ili 60 µg.
18. Farmaceutski pripravak za uporabu u postupku liječenja prema bilo kojem od zahtjeva 13 do 17, naznačen time što se 25-hidroksivitamin D3 oralno primjenjuje jednom dnevno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91385307P | 2007-04-25 | 2007-04-25 | |
EP19172946.6A EP3542792B1 (en) | 2007-04-25 | 2008-04-25 | Controlled release 25-hydroxyvitamin d |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231142T3 true HRP20231142T3 (hr) | 2024-01-05 |
Family
ID=39665965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231142TT HRP20231142T3 (hr) | 2007-04-25 | 2008-04-25 | Kontrolirano oslobađanje 25-hidroksivitamina d |
Country Status (16)
Country | Link |
---|---|
US (8) | US8361488B2 (hr) |
EP (6) | EP3542792B1 (hr) |
JP (4) | JP5501956B2 (hr) |
KR (6) | KR20190028822A (hr) |
CN (2) | CN104523707B (hr) |
CA (2) | CA2943032C (hr) |
DK (3) | DK3342405T3 (hr) |
ES (4) | ES2956794T3 (hr) |
HK (4) | HK1142013A1 (hr) |
HR (1) | HRP20231142T3 (hr) |
HU (1) | HUE063590T2 (hr) |
NO (1) | NO2020043I1 (hr) |
PL (3) | PL3542792T3 (hr) |
PT (3) | PT2481400E (hr) |
SI (2) | SI2481400T1 (hr) |
WO (1) | WO2008134512A1 (hr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2640094C (en) | 2006-02-03 | 2015-04-14 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
PT3357496T (pt) | 2006-06-21 | 2020-05-12 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
CN101668532B (zh) * | 2007-04-25 | 2014-08-20 | 赛特克罗公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 |
JP5501956B2 (ja) | 2007-04-25 | 2014-05-28 | シトクロマ インコーポレイテッド | ビタミンd化合物およびワックス状担体を含有する制御放出性経口組成物 |
WO2008134518A2 (en) * | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
EP2148683A4 (en) | 2007-04-25 | 2012-09-12 | Proventiv Therapeutics Llc | METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYREOSIS IN CHRONIC KIDNEY DISEASE |
US20090060879A1 (en) * | 2007-09-04 | 2009-03-05 | The Procter & Gamble Company | Oral Compositions, Products and Methods Of Use |
US20110039811A1 (en) * | 2008-02-12 | 2011-02-17 | Neil Robert Buck | Treating hyperglycemia with 25-hydroxyvitamin d3 |
BRPI0907953A2 (pt) * | 2008-02-13 | 2015-08-04 | Dsm Ip Assets Bv | Uso de 25-hidroxivitamina d3 para afetar a fisiologia do músculo humano |
AU2009214049B2 (en) * | 2008-02-13 | 2014-02-06 | Dsm Ip Assets B.V. | Combination of vitamin D and 25-hydroxyvitamin D 3 |
CA2714996C (en) | 2008-04-02 | 2020-04-07 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
RU2571946C2 (ru) | 2008-06-26 | 2015-12-27 | Орпхасиме Апс | Применение hsp70 в качестве регулятора ферментативной активности |
ES2525180T3 (es) * | 2008-07-24 | 2014-12-18 | Wisconsin Alumni Research Foundation | Administración semanal de 25-hidroxi-vitamina D3 para mantener una concentración en sangre con farmacocinética en estado de equilibrio elevada |
JP2013506689A (ja) * | 2009-09-30 | 2013-02-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 補因子、及び個人に対するその使用方法 |
EP2515866B1 (en) * | 2009-12-22 | 2014-02-19 | Leo Pharma A/S | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
CA2785251A1 (en) * | 2009-12-22 | 2011-06-30 | Leo Pharma A/S | Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
CN105796530A (zh) | 2010-03-29 | 2016-07-27 | 赛特克罗公司 | 用于降低甲状旁腺水平的方法和组合物 |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9662375B2 (en) | 2010-11-30 | 2017-05-30 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
CA2860284C (en) * | 2011-03-02 | 2019-02-05 | D3 Pharma Limited | Vitamin d composition |
JP6049409B2 (ja) * | 2012-11-08 | 2016-12-21 | 中日本カプセル 株式会社 | ハードカプセルの製造方法 |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CN103142554B (zh) * | 2013-03-21 | 2014-11-12 | 青岛正大海尔制药有限公司 | 骨化三醇控释胶囊及其制备方法 |
US9707242B2 (en) * | 2013-03-27 | 2017-07-18 | Dsm Ip Assets B.V. | Use of 25-hydroxyvitamin D3 to enhance executive functions |
US20140296190A1 (en) * | 2013-03-27 | 2014-10-02 | Dsm Ip Assets B.V. | Marketing the use of 25-hydroxyvitamin d3 to enhance cognition |
WO2015102996A1 (en) * | 2013-12-31 | 2015-07-09 | Grasso Frank J | Extremely high loading dose |
TWI812891B (zh) * | 2014-03-14 | 2023-08-21 | 開曼群島商歐科二代智財控股公司 | 經穩定之修飾釋放維他命d調配物及其服用方法 |
TWI645864B (zh) * | 2014-03-14 | 2019-01-01 | 歐科二代智財控股公司 | 經穩定之修飾釋放維他命d調配物及其服用方法 |
AU2015298858A1 (en) * | 2014-08-07 | 2017-03-02 | Opko Ireland Global Holdings Ltd. | Adjunctive therapy with 25-hydroxyvitamin D |
KR102487452B1 (ko) | 2014-09-15 | 2023-01-10 | 오르파짐 에이/에스 | 아리모클로몰 제제 |
JP6910950B2 (ja) * | 2015-01-12 | 2021-07-28 | エンテリス・バイオファーマ・インコーポレイテッドEnteris Biopharma,Inc. | 固形経口剤形 |
EP3053598A1 (en) * | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
US20180169034A1 (en) * | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
JP6851868B2 (ja) * | 2016-03-23 | 2021-03-31 | 株式会社ファンケル | ビタミンd3安定化組成物 |
IL290855B1 (en) * | 2016-03-28 | 2024-02-01 | Eirgen Pharma Ltd | Treatment methods using vitamin D |
EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
CN109069496A (zh) | 2016-04-29 | 2018-12-21 | 奥菲泽米有限公司 | 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol |
KR102108153B1 (ko) * | 2017-07-05 | 2020-05-07 | (주)동구바이오제약 | 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물 |
KR20200140284A (ko) * | 2018-04-03 | 2020-12-15 | 옵코 아일랜드 글로벌 홀딩스 리미티드 | 비만대사 수술 환자에서의 칼시페디올의 용도 |
MX2020011740A (es) | 2018-08-31 | 2021-04-19 | Opko Ireland Global Holdings Ltd | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso. |
EP3920938A1 (en) | 2019-02-06 | 2021-12-15 | EirGen Pharma Ltd. | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
EP3708171A1 (en) * | 2019-03-11 | 2020-09-16 | Roger Bouillon | Treatment of vitamin d deficiency with 25(oh) vitamin d in critically ill patients |
WO2021050697A1 (en) * | 2019-09-11 | 2021-03-18 | Barlean's Organic Oils, Llc | Softgel fill materials |
US20210308151A1 (en) * | 2020-04-06 | 2021-10-07 | Eirgen Pharma Ltd. | Activating endogenous antimicrobials to treat sars-cov-2 infection |
MX2022012599A (es) * | 2020-04-07 | 2022-11-07 | Carbogen Amcis B V | 25-hidroxivitamina d2 y/o d3 para usarse en la obesidad. |
IL297885A (en) * | 2020-05-31 | 2023-01-01 | Eirgen Pharma Ltd | Hard capsule dosage form and its uses |
CA3202568A1 (en) | 2020-11-19 | 2022-05-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (250)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3565924A (en) * | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
US3880894A (en) * | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
US4004003A (en) * | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
US4335120A (en) * | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4230701A (en) * | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
JPS5832823A (ja) | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | 脱癌剤 |
JPS5832823U (ja) | 1981-08-27 | 1983-03-03 | 銅金株式会社 | 金属屋根板用吊子 |
JPS58206524A (ja) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
JPS59155309A (ja) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | 活性型ビタミンd↓3類組成物 |
US4684524A (en) * | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
US4555364A (en) * | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
US4668517A (en) * | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
JPS61293911A (ja) | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US5104864A (en) * | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンd▲下3▼類固型製剤 |
JPH02240024A (ja) | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンd↓3類製剤用組成物 |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
GB9004544D0 (en) * | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
JP2845342B2 (ja) | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンd▲下3▼誘導体含有固形製剤組成物 |
JPH04198129A (ja) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 活性型ビタミンd↓3類含有組成物 |
JP2893140B2 (ja) | 1990-11-30 | 1999-05-17 | エスエス製薬株式会社 | 安定なビタミンd製剤 |
JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンd3類軟カプセル剤の製造方法 |
CA2065603C (en) * | 1991-04-09 | 2007-04-03 | Hiroki Itoh | Stabilized vitamin d preparation |
US5693615A (en) * | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
JP3722832B2 (ja) * | 1992-06-22 | 2005-11-30 | ルーナー、コーポレーション | 経口用1α−ヒドロキシプレビタミンD |
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
JPH07242550A (ja) | 1994-03-02 | 1995-09-19 | Teijin Ltd | 二次性副甲状腺機能亢進症治療剤 |
IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
CA2195623A1 (en) | 1994-07-22 | 1996-02-08 | Rajeev D. Gokhale | Self-emulsifying drug delivery system |
JPH0892098A (ja) | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
EP0787122B9 (en) | 1994-10-21 | 2007-10-17 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
US6376479B1 (en) * | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
JP3372259B2 (ja) | 1995-09-21 | 2003-01-27 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | カルシトリオール誘導体およびそれらの用途 |
DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
NO971934L (no) | 1996-05-23 | 1997-11-24 | Hoffmann La Roche | Flourinerte vitamin D3 -analoger |
US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
ATE226078T1 (de) * | 1996-08-26 | 2002-11-15 | Takeda Chemical Industries Ltd | Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol |
US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
AU744156B2 (en) | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
JPH10158171A (ja) | 1996-12-02 | 1998-06-16 | Kita:Kk | ビタミンd化合物を配合した眼内投与剤 |
US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
WO1999001111A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
JPH1175863A (ja) | 1997-07-10 | 1999-03-23 | Kyowa Hakko Kogyo Co Ltd | 25−ヒドロキシビタミンD3−1α−水酸化酵素および該酵素をコードするDNA |
US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
JPH11158074A (ja) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | 高アミノ酸付加活性型ビタミンd強化組成物 |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
CA2323782A1 (en) | 1998-03-25 | 1999-09-30 | Cutanogen, Inc. | Methods for prevention and treatment of cancer |
ATE515265T1 (de) | 1998-03-27 | 2011-07-15 | Univ Oregon Health & Science | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US8133694B2 (en) | 1998-06-25 | 2012-03-13 | Immundiagnostik Ag | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D |
US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
EA002720B1 (ru) | 1998-08-27 | 2002-08-29 | Фармациа Энд Апджон Аб | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием |
SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
ATE429813T1 (de) | 1998-10-09 | 2009-05-15 | Gen Mills Inc | Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel |
JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
JP2000206312A (ja) | 1998-11-12 | 2000-07-28 | Olympus Optical Co Ltd | 光学素子 |
EP1140012B1 (en) * | 1998-12-17 | 2004-03-03 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6432936B1 (en) * | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE60031666T2 (de) * | 1999-04-01 | 2007-08-30 | The Johns Hopkins University | NICHT-CALCEMISCHE, TRANSKRIPTIONELL-AKTIVE, SCHWEFELHALTIGE ANALOGA VON 1-alpha, 25-DIHYDROXYVITAMIN D3 MIT ANTIPROLIFERATIVER WIRKUNG |
US7648826B1 (en) | 1999-04-02 | 2010-01-19 | The Regents Of The University Of California | Detecting CYP24 expression level as a marker for predisposition to cancer |
DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
WO2000072831A1 (en) * | 1999-05-27 | 2000-12-07 | Drugtech Corporation | Nutritional formulations |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US6051567A (en) * | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
US6274169B1 (en) * | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
US6893658B1 (en) | 1999-08-31 | 2005-05-17 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
JP2004504295A (ja) * | 2000-07-18 | 2004-02-12 | ボーン ケア インターナショナル インコーポレイテッド | 安定化1α−ヒドロキシビタミンD |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
RU2003108732A (ru) | 2000-08-29 | 2004-07-27 | Ниссин Касей Ко., Лтд. (Jp) | Жесткая капсула |
US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
KR100968128B1 (ko) | 2000-10-30 | 2010-07-06 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US6479649B1 (en) | 2000-12-13 | 2002-11-12 | Fmc Corporation | Production of carrageenan and carrageenan products |
JP2002302447A (ja) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | 局所投与用癌治療剤 |
MXPA03009805A (es) | 2001-05-15 | 2005-03-07 | Warner Lambert Co | Procedimiento de compactacion para fabricar una forma de dosificacion de fenitoina sodica. |
WO2003004003A1 (fr) | 2001-07-05 | 2003-01-16 | Wakunaga Pharmaceutical Co., Ltd. | Capsules molles |
US6870833B2 (en) | 2001-07-20 | 2005-03-22 | Net2Phone, Inc. | Active voice messaging |
US7166585B2 (en) | 2001-08-22 | 2007-01-23 | Cytochroma Inc. | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
KR100688618B1 (ko) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | 비타민 d 경구투여용 서방성 약제 조성물 |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
ATE360000T1 (de) * | 2001-10-12 | 2007-05-15 | Univ Johns Hopkins | Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung |
US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
CA2466996C (en) | 2001-11-22 | 2010-09-14 | Morishita Jintan Co., Ltd. | Non-gelatinous capsule shell compositions and capsules using the same |
GB0128415D0 (en) | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
FR2829142B1 (fr) | 2001-12-27 | 2004-02-13 | Ulice | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues |
US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US6949256B2 (en) | 2002-01-18 | 2005-09-27 | Banner Pharmacaps, Inc. | Non-gelatin capsule shell formulation |
NO20021592D0 (no) | 2002-04-04 | 2002-04-04 | Fmc Biopolymer As | Polysakkaridkapsler og fremgangsmåte ved fremstilling derav |
US20050176685A1 (en) | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
AU2003220689A1 (en) | 2002-04-10 | 2003-10-27 | Miller, Fred H | Multi-phase, multi-compartment capsular system |
US7288407B2 (en) | 2002-05-02 | 2007-10-30 | Cytochroma, Inc. | Stable cytochrome P450 24 (CYP24) expressing cell line and methods and uses thereof |
ES2380748T3 (es) | 2002-06-13 | 2012-05-18 | Johns Hopkins University | Compuestos de 24-sulfoximina vitamina D3 |
AU2003244840C1 (en) | 2002-07-05 | 2010-03-04 | Temrel Limited | Controlled release composition |
TWI336260B (en) | 2002-07-25 | 2011-01-21 | Glaxo Group Ltd | Dosage form suitable for retaining drug substance |
CN1684670A (zh) | 2002-07-29 | 2005-10-19 | 阿尔扎公司 | 用于控制释放帕潘立酮的方法和剂型 |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
WO2004028515A1 (en) | 2002-09-26 | 2004-04-08 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2004175750A (ja) | 2002-11-28 | 2004-06-24 | Kose Corp | 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤 |
US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
DE20321698U1 (de) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats |
GB2411116B (en) | 2002-12-16 | 2009-04-29 | Teva Pharma | Increasing the bioavailability of alendronate by predose administration of alphacalcidol |
CA2510228C (en) | 2002-12-18 | 2012-10-30 | Johns Hopkins University | 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3 |
JP2006517593A (ja) | 2003-02-11 | 2006-07-27 | アルザ・コーポレーシヨン | 投薬形態物の層形状修飾方法およびそのような修飾を受けさせた投薬形態物 |
US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
EP1620059A2 (en) | 2003-04-14 | 2006-02-01 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
WO2004098507A2 (en) | 2003-04-30 | 2004-11-18 | Bioxell S.P.A. | 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
AU2004237437B2 (en) | 2003-05-07 | 2011-01-20 | Osteologix A/S | Controlled release composition containing a strontium salt |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
JP2007526013A (ja) | 2003-06-16 | 2007-09-13 | ソルクス インコーポレイテッド | 緑内障を治療するためのシャント装置 |
JP5628467B2 (ja) | 2003-06-26 | 2014-11-19 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 生体分解性徐放性ドラッグデリバリーシステム |
AU2003903382A0 (en) | 2003-07-03 | 2003-07-17 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof |
KR20060105735A (ko) | 2003-07-04 | 2006-10-11 | 니코메드 덴마크 에이피에스 | 경구용 부갑상선 호르몬 함유 약학 조성물 |
US20050148557A1 (en) | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
US20050124591A1 (en) * | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
PL2821067T3 (pl) | 2003-09-12 | 2018-02-28 | Amgen Inc. | Szybko rozpuszczający się preparat cynakalcetu |
EP1694333A2 (en) | 2003-11-25 | 2006-08-30 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
CA2494572A1 (en) | 2003-12-19 | 2005-06-19 | Cytochroma Inc. | Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
JP2008502605A (ja) | 2004-06-16 | 2008-01-31 | スマート ドラッグ システムズ インコーポレイティド | 徐放性ワクチン組成物 |
WO2006007323A2 (en) | 2004-06-28 | 2006-01-19 | Alza Corporation | Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
JP2008508227A (ja) | 2004-07-29 | 2008-03-21 | サノフイ−アベンテイス | 高ph依存性溶解度を有する有効成分の放出制御のための医薬品多層錠剤 |
US8231896B2 (en) | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
WO2006059180A2 (en) | 2004-12-03 | 2006-06-08 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
CA2604943C (en) | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
US9205047B2 (en) | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
AR055099A1 (es) | 2005-07-28 | 2007-08-08 | Alza Corp | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol |
CA2624124A1 (en) | 2005-09-29 | 2007-04-12 | F. Hoffmann-La Roche Ag | Antibodies against 25-hydroxyvitamin d |
ITFI20050206A1 (it) | 2005-09-30 | 2007-04-01 | Valpharma Sa | Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione |
EP3047847A1 (en) * | 2005-10-12 | 2016-07-27 | OPKO Renal, LLC | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
US8293270B2 (en) | 2005-10-26 | 2012-10-23 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system |
JP5406530B2 (ja) | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
EA200801223A1 (ru) | 2005-11-01 | 2009-06-30 | СиПи КЕЛКО Ю.С., ИНК. | Пленки и капсулы, сделанные из модифицированных карбоксиметилцеллюлозных материалов, и способы их изготовления |
WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
MXPA05014091A (es) | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus |
US20070207488A1 (en) | 2006-01-31 | 2007-09-06 | Trump Donald L | Method for identifying altered vitamin D metabolism |
US7528122B2 (en) | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
CA2640094C (en) * | 2006-02-03 | 2015-04-14 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
GB0606426D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
JP2009540053A (ja) | 2006-06-06 | 2009-11-19 | エフ エム シー コーポレーション | カッパー−2カラギーナン組成物及びそれからつくられた製品 |
US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
PT3357496T (pt) | 2006-06-21 | 2020-05-12 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
EP1912400A1 (en) | 2006-10-10 | 2008-04-16 | Matsushita Electric Industrial Co., Ltd. | Method and apparatus for mobile IP route optimization |
US20100168410A1 (en) | 2006-10-27 | 2010-07-01 | Pfizer Products Inc. | Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture |
WO2008097646A1 (en) | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
US8491937B2 (en) | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
EP2135345A4 (en) | 2007-03-20 | 2016-12-14 | Electrolock Inc | ROEBEL WINDING WITH CONDUCTIVE FELT |
US20100144679A1 (en) | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
WO2008134518A2 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
EP2148683A4 (en) | 2007-04-25 | 2012-09-12 | Proventiv Therapeutics Llc | METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYREOSIS IN CHRONIC KIDNEY DISEASE |
CN101668532B (zh) | 2007-04-25 | 2014-08-20 | 赛特克罗公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 |
JP5501956B2 (ja) | 2007-04-25 | 2014-05-28 | シトクロマ インコーポレイテッド | ビタミンd化合物およびワックス状担体を含有する制御放出性経口組成物 |
US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
KR100836960B1 (ko) | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | 새로운 나이아신 제어방출형 제제 |
EP2042165A1 (de) | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
AU2007362356A1 (en) | 2007-12-12 | 2009-06-18 | Northern Innovations And Formulations Corp. | Particles in a capsule |
US20110039811A1 (en) | 2008-02-12 | 2011-02-17 | Neil Robert Buck | Treating hyperglycemia with 25-hydroxyvitamin d3 |
AU2009214049B2 (en) | 2008-02-13 | 2014-02-06 | Dsm Ip Assets B.V. | Combination of vitamin D and 25-hydroxyvitamin D 3 |
AU2009214048A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Treating hypertension with 25-hydroxyvitamin D3 |
BRPI0907953A2 (pt) | 2008-02-13 | 2015-08-04 | Dsm Ip Assets Bv | Uso de 25-hidroxivitamina d3 para afetar a fisiologia do músculo humano |
CN101951919A (zh) | 2008-02-13 | 2011-01-19 | 帝斯曼知识产权资产管理有限公司 | 维生素d3和25-羟基-维生素d3用于治疗骨质疏松症和改善骨矿物质密度的组合用途 |
CA2714996C (en) | 2008-04-02 | 2020-04-07 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
ES2525180T3 (es) | 2008-07-24 | 2014-12-18 | Wisconsin Alumni Research Foundation | Administración semanal de 25-hidroxi-vitamina D3 para mantener una concentración en sangre con farmacocinética en estado de equilibrio elevada |
US9757343B2 (en) | 2008-09-24 | 2017-09-12 | Evonik Röhm Gmbh | PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
EP2179727B1 (en) | 2008-10-27 | 2013-05-29 | Roquette Freres | Water insoluble polymer: modified starch derivative-based film coatings for colon targeting |
BRPI1006902A2 (pt) | 2009-01-23 | 2016-02-16 | Aziende Chimiche Riunte Angelini Francesco A C R A F S P A | formulação farmacêutica ou alimentícia de liberação controlada, processo para a produção de uma forma farmacêutica ou alimentícia, sistema de liberação controlada, e, uso de um sistema de liberação controlada |
CH700543A2 (de) | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
US9895672B2 (en) | 2009-09-10 | 2018-02-20 | DuPont Nutrition USA, Inc. | High strength seamless alginate capsules |
IT1396937B1 (it) | 2009-11-26 | 2012-12-20 | Bruzzese | Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea |
FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
US8101203B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
CN105796530A (zh) | 2010-03-29 | 2016-07-27 | 赛特克罗公司 | 用于降低甲状旁腺水平的方法和组合物 |
EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
KR20120005228A (ko) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법 |
BR112013002721B8 (pt) | 2010-08-04 | 2021-05-25 | Scherer Technologies Llc R P | composição formadora de filme para cápsulas moles, cápsulas moles e seu invólucro |
US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
CN103237552B (zh) | 2010-12-06 | 2018-03-06 | 帝斯曼知识产权资产管理有限公司 | 用25‑羟基‑维生素d3治疗与嗜酸性粒细胞趋化因子增高有关的病症 |
JP6138053B2 (ja) | 2010-12-28 | 2017-05-31 | フューチャー・ダイアグノスティックス・ベーフェー | ビタミンdのための放出試薬 |
CA2860284C (en) | 2011-03-02 | 2019-02-05 | D3 Pharma Limited | Vitamin d composition |
ES2617654T3 (es) | 2011-04-20 | 2017-06-19 | Suheung Co., Ltd. | Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas |
EA201391553A1 (ru) | 2011-04-20 | 2014-03-31 | Майко Байо, Инк. | Композиция и способ усиления иммунного ответа |
CN102771688A (zh) | 2011-05-13 | 2012-11-14 | 富曼实(上海)商贸有限公司 | 可食用液体填充的多糖胶囊 |
US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
PT106978A (pt) | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
EP2815745A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte und Lizenzen AG | Soft shell capsule and process for its manufacture |
CN103495176B (zh) | 2013-10-26 | 2015-01-28 | 中山市凯博思淀粉材料科技有限公司 | 一种共混挤出法制备淀粉基软胶囊的方法 |
CN103520133B (zh) | 2013-10-26 | 2015-02-04 | 中山市凯博思淀粉材料科技有限公司 | 一种淀粉基软胶囊的制备方法 |
AU2015298858A1 (en) | 2014-08-07 | 2017-03-02 | Opko Ireland Global Holdings Ltd. | Adjunctive therapy with 25-hydroxyvitamin D |
-
2008
- 2008-04-25 JP JP2010506520A patent/JP5501956B2/ja active Active
- 2008-04-25 PL PL19172946.6T patent/PL3542792T3/pl unknown
- 2008-04-25 DK DK18154616T patent/DK3342405T3/da active
- 2008-04-25 ES ES19172946T patent/ES2956794T3/es active Active
- 2008-04-25 CN CN201510005755.5A patent/CN104523707B/zh active Active
- 2008-04-25 KR KR1020197007218A patent/KR20190028822A/ko not_active Application Discontinuation
- 2008-04-25 DK DK08746908.6T patent/DK2148661T3/da active
- 2008-04-25 KR KR1020177019172A patent/KR101959952B1/ko active IP Right Grant
- 2008-04-25 CA CA2943032A patent/CA2943032C/en active Active
- 2008-04-25 ES ES08746908T patent/ES2401205T3/es active Active
- 2008-04-25 KR KR1020167036353A patent/KR101759244B1/ko active IP Right Grant
- 2008-04-25 HR HRP20231142TT patent/HRP20231142T3/hr unknown
- 2008-04-25 ES ES12154573.5T patent/ES2496915T3/es active Active
- 2008-04-25 ES ES18154616T patent/ES2757517T3/es active Active
- 2008-04-25 EP EP19172946.6A patent/EP3542792B1/en active Active
- 2008-04-25 PT PT121545735T patent/PT2481400E/pt unknown
- 2008-04-25 CN CN200880013357.6A patent/CN101668517B/zh active Active
- 2008-04-25 KR KR1020097024328A patent/KR101540369B1/ko active IP Right Grant
- 2008-04-25 EP EP18154616.9A patent/EP3342405B1/en active Active
- 2008-04-25 SI SI200831282T patent/SI2481400T1/sl unknown
- 2008-04-25 PL PL08746908T patent/PL2148661T3/pl unknown
- 2008-04-25 KR KR1020147030441A patent/KR101691876B1/ko active IP Right Grant
- 2008-04-25 US US12/109,983 patent/US8361488B2/en active Active
- 2008-04-25 EP EP12154573.5A patent/EP2481400B1/en active Active
- 2008-04-25 PT PT181546169T patent/PT3342405T/pt unknown
- 2008-04-25 EP EP23175825.1A patent/EP4248952A1/en active Pending
- 2008-04-25 EP EP08746908A patent/EP2148661B1/en active Active
- 2008-04-25 EP EP14166756.8A patent/EP2762132A1/en not_active Ceased
- 2008-04-25 SI SI200830899T patent/SI2148661T1/sl unknown
- 2008-04-25 CA CA2683997A patent/CA2683997C/en active Active
- 2008-04-25 DK DK12154573.5T patent/DK2481400T3/da active
- 2008-04-25 KR KR1020197036963A patent/KR20190141269A/ko not_active Application Discontinuation
- 2008-04-25 WO PCT/US2008/061579 patent/WO2008134512A1/en active Application Filing
- 2008-04-25 PL PL12154573T patent/PL2481400T3/pl unknown
- 2008-04-25 PT PT87469086T patent/PT2148661E/pt unknown
- 2008-04-25 HU HUE19172946A patent/HUE063590T2/hu unknown
-
2010
- 2010-09-10 HK HK10108648.7A patent/HK1142013A1/zh unknown
-
2011
- 2011-09-26 US US13/244,945 patent/US8207149B2/en active Active
-
2013
- 2013-01-22 US US13/746,982 patent/US8778373B2/en active Active
- 2013-02-01 HK HK13101470.2A patent/HK1174538A1/xx unknown
- 2013-11-22 JP JP2013241875A patent/JP5931042B2/ja active Active
-
2014
- 2014-06-16 US US14/305,863 patent/US9918940B2/en active Active
-
2015
- 2015-02-06 HK HK15101345.3A patent/HK1200732A1/xx unknown
- 2015-04-17 US US14/690,131 patent/US9408858B2/en active Active
- 2015-10-13 HK HK15109994.0A patent/HK1209322A1/xx unknown
-
2016
- 2016-04-26 JP JP2016087776A patent/JP6236657B2/ja active Active
- 2016-08-08 US US15/231,357 patent/US9498486B1/en active Active
- 2016-11-21 US US15/358,065 patent/US9925147B2/en active Active
-
2017
- 2017-10-04 JP JP2017194134A patent/JP6530028B2/ja active Active
- 2017-10-05 US US15/726,046 patent/US11154509B2/en active Active
-
2020
- 2020-12-02 NO NO2020043C patent/NO2020043I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
JP2017002086A5 (hr) | ||
HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
JP6363104B2 (ja) | 15−ohepaを含む組成物および同組成物を使用する方法 | |
JP2010525078A5 (hr) | ||
HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
JP2015519404A5 (hr) | ||
EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
JP2008044951A5 (hr) | ||
EP3390367B1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
JP2014528474A5 (hr) | ||
TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
JP2015535209A5 (hr) | ||
JP2018507243A5 (hr) | ||
CA2563058A1 (en) | Supportive treatment of liver disease | |
HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
JP2013541583A5 (hr) | ||
JP2015522015A5 (hr) | ||
JP2006503031A5 (hr) | ||
JP2016505050A5 (hr) | ||
US9056139B2 (en) | Fatty acid-salicylate conjugates with enhanced therapeutic properties | |
JP2009534367A5 (hr) |